Alpine Immune Sciences Inc (ALPN)
64.97
0.00 (0.00%)
USD |
NASDAQ |
May 20, 16:00
Alpine Immune Sciences Research and Development Expense (Quarterly): 22.46M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 22.46M |
December 31, 2023 | 22.93M |
September 30, 2023 | 19.15M |
June 30, 2023 | 19.24M |
March 31, 2023 | 19.58M |
December 31, 2022 | 18.76M |
September 30, 2022 | 17.59M |
June 30, 2022 | 17.59M |
March 31, 2022 | 16.31M |
December 31, 2021 | 15.36M |
September 30, 2021 | 18.31M |
June 30, 2021 | 14.63M |
March 31, 2021 | 10.44M |
December 31, 2020 | 9.055M |
September 30, 2020 | 6.156M |
June 30, 2020 | 7.096M |
March 31, 2020 | 4.878M |
December 31, 2019 | 5.799M |
September 30, 2019 | 9.532M |
June 30, 2019 | 10.17M |
March 31, 2019 | 10.35M |
Date | Value |
---|---|
December 31, 2018 | 8.931M |
September 30, 2018 | 10.53M |
June 30, 2018 | 5.718M |
March 31, 2018 | 3.792M |
December 31, 2017 | 3.71M |
September 30, 2017 | 2.75M |
June 30, 2017 | 0.359M |
March 31, 2017 | 2.758M |
December 31, 2016 | 5.656M |
September 30, 2016 | 5.669M |
June 30, 2016 | 6.424M |
March 31, 2016 | 5.567M |
December 31, 2015 | 4.293M |
September 30, 2015 | 4.279M |
June 30, 2015 | 4.465M |
March 31, 2015 | 3.017M |
December 31, 2014 | 2.822M |
September 30, 2014 | 2.164M |
June 30, 2014 | 3.363M |
March 31, 2014 | 3.851M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.878M
Minimum
Mar 2020
22.93M
Maximum
Dec 2023
14.25M
Average
15.84M
Median
Research and Development Expense (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 789.10M |
Eliem Therapeutics Inc | 1.091M |
Regeneron Pharmaceuticals Inc | 1.248B |
Vera Therapeutics Inc | 23.20M |
Eyenovia Inc | 4.432M |